BVS
Bioventus, Inc. Class A · NASDAQ
- Sector Health Technology
- Industry Medical Specialties
- Website bioventus.com
- Employees(FY) 970
- ISIN US09075A1088
Performance
-4.22%
1W
-7.94%
1M
-7.94%
3M
+83.33%
6M
+102.47%
YTD
+104.8%
1Y
Profile
Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices used for precise bone sculpting, removing tumors, and tissue debridement. The company's restorative therapies include a bone healing system; skin allografts; and products that are used to support healing of wounds, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Technical Analysis of BVS 2024-12-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-17 07:31
- 2024-12-06 09:55
- 2024-11-06 02:43
Q3 2024 Bioventus Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-11-06 02:14
- 2024-11-05 09:50
- 2024-11-05 08:45
- 2024-11-05 07:41
Bioventus: Q3 Earnings Snapshot(Associated Press Finance)
- 2024-11-05 07:30
Bioventus Reports Third Quarter Financial Results(GlobeNewswire)
- 2024-11-04 18:30
Bioventus Reports Third Quarter Financial Results(Globenewswire)
- 2024-11-04 09:40
- 2024-11-04 07:09
- 2024-10-29 09:35
- 2024-10-29 07:30
- 2024-10-28 19:30
- 2024-10-25 16:53
Bioventus Files $200 Million Mixed-Shelf Offering(MT Newswires)
- 2024-10-22 09:35
- 2024-10-18 09:40
- 2024-10-15 16:01
Solventum Stock Earns 81 RS Rating(Investor's Business Daily)
- 2024-10-09 17:03
- 2024-10-01 09:30
- 2024-10-01 09:00
- 2024-09-30 21:00
- 2024-09-27 13:40
- 2024-09-26 11:40
- 2024-09-24 11:46
- 2024-09-24 08:40
- 2024-09-23 15:05
- 2024-09-20 13:33
- 2024-09-19 13:00
- 2024-09-19 12:48
Page 1 of 6
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.